Huang Qiang
Soochow University (Taiwan)
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Huang Qiang.
Journal of Cancer Research and Clinical Oncology | 2009
Yao Jin; Zhang Bin; Huang Qiang; Chu Liang; Chen Hua; Dong Jun; Wang Ai Dong; Lan Qing
ObjectiveThe aim of this study is to explore if ABCG2 is related to the grade of glioma and resistance to chemotherapeutic drug for glioma.MethodsThe ABCG2 expression and distribution among glioma tissues of different grades and other samples were examined using tissue microarray technique. The enhancement of sensitivity of CD133+ glioma stem cells to chemotherapeutic agent, mitoxantone through addition of ABCG2 competitive inhibitor nicardipine was testified by MTT assay and FACS analysis.ResultsThe positive immunostaining of ABCG2 was observed in less than 10% of low-grade gliomas (3/31 in grade Ixa0+xa0II) and in more than 40% of high-grade gliomas (16/37 in grade IIIxa0+xa0IV), which was statistically different (χ2xa0=xa010.710, Pxa0=xa00.0011). In samples consisting of glioma stem cells (CD133+), the positive-straining rate was 100% (4/4), while in CD133− fraction, no positive staining was observed. A simultaneous treatment of CD133+ tumor cells with concentration-dependent mitoxantone (10−5–1xa0µM) and 2.5/5.0xa0µM nicardipine resulted in synergistic cytotoxicity. The apoptotic rate of CD133+ cells treated with mitoxantone plus nicardipine was significantly higher than that treated with mitoxantone alone (58.54xa0±xa07.06% vs. 30.7xa0±xa03.79%, Pxa0<xa00.01).ConclusionsOur results showed that ABCG2 is also expressed in glioma stem cells and the expression level of ABCG2 is positively associated with the increasing pathological grade of glioma (poor cell differentiation). ABCG2 plays a key role in glioma cells resistance to mitoxantone, chemotherapeutic drug for glioma. Thus, inhibition of ABCG2 protein activity by nicardipine in glioma can sensitize it to mitoxantone, which may lead to better treatment strategies for cancers.
Archive | 2015
Wang Aijun; Huang Qiang; Zhou Jingdu; Yang Pingping; Luo Chunlin; Li Yu; Wei Xinchun; Wu Wenjing; Jia Binbin
Archive | 2016
Wang Yanxiang; Wang Huitang; Huang Qiang; Yu Haiyang; Ge Jiangfeng; Gu Kai; Jiang Xu; Zhang Ying; Xia Xinyu; Qi Yaming; Gu Xinjun; Zhai Bo; Shi Lei; Hu Rui; Wang Jianxiu
Archive | 2016
Huang Qiang; Jiang Xu; Wang Deng; Jiang Li; Liu Jingyu; Zhang Kanyi; Xia Xinyu; Zhang Bin; Zhai Bo; Meng Xiangsheng; Wu Qin; Ling Yong; Zhang Zhaosheng; Wu Di; Gu Kai; Li Yang; Li Weiquan; Li Bo
Archive | 2015
Wang Aijun; Huang Qiang; Xie Liang; Yang Pingping; Ning Jiangping; Wang Yifu; Gu Xinjun; Wang Zhifu; Song Junpei; Shan Guoping; Xu Bin; Gou Kaihai
Archive | 2015
Yang Pingping; Huang Qiang; Wang Aijun; Mei Jun; Luo Chunlin; Fu Lei; Zhou Jingdu; Zheng Liusun; Zheng Shuai
Archive | 2015
Luo Chunlin; Huang Qiang; Yang Pingping; Wang Dayong; Zhao Meigang; Wang Aijun; Cao Jun; Zheng Shuai
Archive | 2014
Huang Qiang; Ling Yong; Luo Wei; Wang Kangjun; Li Yu; Jiang Xu; Zhang Kanyi; Fan Yuxin; Zhao Bo; Hu Xinyu; Sha Junjie; Li Chun; Gu Kai
Archive | 2014
Huang Qiang; Sha Junjie; Yang Pingping; Gu Kai; Wang Aijun; Zhou Jingdu; Mei Jun; Sun Sen; Wang Liang; Ren Mingfeng; Xie Wenzhi
Archive | 2018
Yang Pingping; Huang Qiang; Wang Aijun; Mei Jun; Luo Chunlin; Fu Lei; Zhang Zhiqing; Zheng Shuai; Zhou Jingdu; Ning Jiangping; Ling Yong; Jiang Li